20 items found in 3 pages
Estimands: Answering the right research questions
An estimand is a description of the research question a trial seeks to answer, which can help researchers better understand how their study should be designed and analysed. Estimands also provide a clear way to communicate treatment effects to different stakeholders. This episode of the Trial Talk podcast features Principal Research Fellow Brennan Kahan, exploring how triallists could benefit from using estimands. Brennan also discusses his recent paper which aims to demystify new guidance on the use of estimands. Resources: •The estimands framework: a primer on the ICH E9(R1): www.bmj.com/content/384/bmj-2023-076316 •'We must let the research question drive study methods' opinion piece: www.ncbi.nlm.nih.gov/pmc/articles/PMC9908044/ •Estimands in cluster-randomized trials: choosing analyses that answer the right question: www.ncbi.nlm.nih.gov/pmc/articles/PMC9908044/
2
4/25/2024
Octopus (part 4): Involvement of people affected by MS with Susan Scott
Octopus is a new clinical trial for people living with progressive multiple sclerosis (MS), which is designed and run by the MRC Clinical Trials Unit at UCL. Thanks to its multi-arm multi-stage platform design, Octopus has the potential to transform the way treatments for progressive MS are tested. The trial is now open in the UK and will be recruiting participants for the next few years. The podcast mini-series will explore the trial from different perspectives by talking to neurologists, MS experts and people affected by MS. In the final part, we explore the role of people affected by MS in the Octopus trial. Susan Scott, a pharmaceutical publications specialist and Octopus patient representative, shares her involvement in the trial and explains how PPI has benefited Octopus so far.
14
11/8/2023
Octopus (part 2): Introducing the trial with Jeremy Chataway
Octopus is a new clinical trial for people living with progressive multiple sclerosis (MS), which is designed and run by the MRC Clinical Trials Unit at UCL. Thanks to its multi-arm multi-stage platform design, Octopus has the potential to transform the way treatments for progressive MS are tested. The trial is now open in the UK and will be recruiting participants for the next few years. The podcast mini-series will explore the trial from different perspectives by talking to neurologists, MS experts and people affected by MS. Part 2 of the series explores our Octopus trial in depth. Professor Jeremy Chataway, lead investigator of Octopus, discusses its novel design, the treatments it will test, and the criteria for people to take part. He also explains the data researchers will collect and analyse to find out if a treatment is working.
1
10/24/2023
Optimising treatments with the new MAMS-ROCI design
Innovative platform designs present an opportunity to run faster and more efficient clinical trials. Clinical trials methodology is a research area that looks at how to improve the design, conduct, and analysis of clinical trials. It focuses on developing and implementing new methods to help run trials faster and more efficiently, that will ultimately accelerate the discovery of new treatments. In this episode, methodologist Matteo Quartagno tells us about a new clinical trial design called MAMS-ROCI. It is a type of multi-arm multi-stage design that compares a range of different treatment durations, doses or frequencies to identify the optimal one.
1
9/20/2023
STAMPEDE (part 3): Impact and legacy with Max Parmar and Nick James
STAMPEDE is a long-running trial in advanced prostate cancer, in which nearly 12,000 men have taken part. Thanks to its multi-arm multi-stage platform design, STAMPEDE has tested many different treatments and directly led to improvements in the standard of prostate cancer care several times. This Trial Talk podcast mini-series will explore the trial’s journey from its inception in the early 2000s to the end of patient recruitment in March 2023. In the final part, Max Parmar and Nick James look back over the trial’s impact on clinical practice and platform trial design, and look forward to STAMPEDE2 and their hopes for the future of prostate cancer research. - Further information is available on the STAMPEDE study page at www.mrcctu.ac.uk For questions or feedback on the series, message us at mrcctu.engage@ucl.ac.uk For more information and to access the transcript: bit.ly/3OQWhV8 As a listener, your opinion is very valuable to us. Please help us to improve the podcast in future
7
8/23/2023
Lunch Hour Lectures - Autumn 2009 - Episode 9: Why the courts are as important as hospitals to the nation's health
Lunch Hour Lectures - Autumn 2009 - Episode 9: Why the courts are as important as hospitals to the nation's health Professor Genn will focus on the critical ways in which courts support society and the economy and on how they have directly improved standards of medicine practice and healthcare. She will also discuss new evidence about the link between access to justice and health and consider whether much of what turns up in doctors’ surgeries (including requests for anti-depressants) are in fact the results of an inability to access the courts. Vintage Podcasts - Lunch Hour Lectures
3
7/25/2023
Neonatal infections (part 2): How the NeoSep1 trial will help treat sick newborns
Neonatal sepsis is a life-threatening infection that affects up to 3 million babies per year globally. In an effort to identify better treatments, the NeoSep1 clinical trial evaluates new antibiotic combinations for newborn babies with sepsis. To learn more about the trial, we speak to Adrie Bekker and Cristina Obiero, principal investigators of the trial in South Africa and Kenya, Reenu Thomas, a neonatologist from South Africa, and Francesca Schiavone, the clinical project manager of the NeoSep1 trial in London.
1
6/8/2023
Neonatal infections (part 1): The NeoOBS study and the global challenge of neonatal sepsis
214,000 newborn babies die of sepsis caused by infections that are resistant to antibiotics every year. This is a major problem worldwide, but disproportionally affects low- and middle- income countries. Reenu Thomas and Adrie Bekker, two neonatologists from South Africa, and Francesca Schiavone, clinical project manager at the MRC CTU at UCL in London, discuss the challenges of treating neonatal sepsis and present the results from an observational study (NeoOBS), which assessed mortality rates of babies with sepsis.
2
5/17/2023
123 >